![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
Received July 4, 2006; accepted September 26, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). Numerous clinical case reports have documented that NSAIDs can cause a reduction in the MTX clearance, even at relatively low maintenance dosages used to treat rheumatoid arthritis. Ketoprofen, indomethacin, and diclofenac caused different levels of toxicities in patients receiving MTX, ending fatally in three of four patients receiving ketoprofen (Thyss et al., 1986), two of which had approximately 12-fold higher MTX serum levels. Similar toxicities were found with salicylate (Stewart et al., 1991), ibuprofen (Cassano, 1989), and naproxen (Singh et al., 1986).
MTX is primarily excreted into urine in the unchanged form, and renal handling involves tubular secretion and reabsorption, in addition to glomerular filtration. Renal tubular secretion of MTX has been thought to be a major site of interaction with other drugs (Takeda et al., 2002). The first step is active uptake from the blood across the basolateral membrane into the proximal tubular cells via the organic anion transporters (OATs) 1 and 3 and the reduced folate carrier-1 (Nozaki et al., 2004). Extrusion from the cells across the luminal membrane into the urine is mediated by the ATP-dependent efflux pumps, multidrug resistance proteins (MRPs) 2 and 4 (Masuda et al., 1997; Chen et al., 2002; van Aubel et al., 2002). Furthermore, MTX is recognized by luminal OAT4 (Takeda et al., 2002), which reabsorbs anions from the primary urine back into the tubular cells (Ekaratanawong et al., 2004). The interaction of NSAIDs with MTX uptake at the basolateral membrane has been investigated recently, and the results showed that several NSAIDs inhibited MTX uptake via human OAT1 and OAT3 at clinically relevant concentrations (Takeda et al., 2002). Nevertheless, when studied in rat kidney slices, the interaction was not as potent as presumed, probably because reduced folate carrier-1, which is insensitive to NSAIDs, also contributes significantly to tubular MTX uptake (Nozaki et al., 2004). To date, the effect of NSAIDs on the luminal efflux of MTX via MRP2 and MRP4 has not yet been studied as potential site of this drug-drug interaction.
The expression of MRP2 (Schaub et al., 1997) and MRP4 (van Aubel et al., 2002) in the kidney is restricted to the luminal membrane of the proximal tubule cells. Mutations in the gene encoding MRP2 (ABCC2) causing Dubin-Johnson syndrome, a rare form of conjugated hyperbilirubinemia, can impair high-dose MTX elimination, leading to renal toxicity in vivo (Hulot et al., 2005). Previous studies showed that MRP4-mediated estradiol 17-
-D-glucuronide transport was inhibited potently by several NSAIDs (Reid et al., 2003), suggesting that these drugs might be potential inhibitors of other MRP4 substrates. In addition, luminal efflux transporters may get exposed to relatively high inhibitor concentrations because NSAIDs can be taken up actively into the proximal tubular cells via basolateral OATs (Sekine et al., 1997; Apiwattanakul et al., 1999). The objective of this study was to investigate the interaction potential of NSAIDs with the renal MTX efflux transporters MRP2 and MRP4. For this purpose, we used membrane vesicles isolated from cells overexpressing human MRP2 and MRP4. Our findings show that various NSAIDs inhibit both MRP2- and MRP4-mediated MTX transport, in general with higher inhibitory potency against MRP4. Our study also shows different and sometimes complex inhibitory patterns of the various NSAIDs tested. This is the first study in which this putative drug-drug interaction is examined at the molecular level.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
).
Cell Lines and Culture Conditions. The MRP2-overexpressing MDCKII cell line was kindly provided by Dr. P. Borst (Dutch Cancer Institute, Amsterdam, The Netherlands) and was cultured as described previously (Evers et al., 1998). The nontransfected MDCKII cell line was used as a control. HEK293 cells were grown in DMEM supplemented with 10% fetal calf serum at 37°C under 5% CO2-humidified air.
Generation of Human MRP4 Baculovirus. The Bac-to-Bac system, normally used for protein production in insect cells, was made suitable for protein expression in mammalian cells by cloning the vesicular stomatitis virus G protein cDNA behind the P10 promoter of the pFastBacDual vector. Next, the CMV promoter and Gateway destination elements (cassette that contains the chloramphenicol resistance gene and the ccdB gene flanked by attR1 and attR2 sites) were introduced in the pFastBacDual vector. The human MRP4 was cloned into the Gateway entry vector. The sequence of this MRP4 construct is equal to GenBank accession number NM_005845 [GenBank] except for the I18L polymorphism. This MRP4 cDNA was transferred to the newly constructed Bac-to-Bac vector with the gateway LR reaction. Baculoviruses were produced as described in the Bac-to-Bac manual. As a control, the enhanced yellow fluorescent protein was also cloned into the gateway entry vector (Invitrogen).
Transduction of HEK293 Cells. HEK293 cells were cultured in 182-cm2 flasks until 70% confluence, after which the culture medium was removed and 1.5 ml of virus and 3.5 ml of medium were added. The cells were incubated for 30 to 60 min at 37°C, after which 20 ml of medium was added. After 24 h of transduction, sodium butyrate (5 mM) was added. Three days after transduction, the cells were harvested.
Isolation of Membrane Vesicles and Protein Analysis. Cells were harvested by centrifugation at 3000g for 30 min. The pellets were resuspended in ice-cold homogenization buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.4) supplemented with protease inhibitors (100 µM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 µM pepstatin, and 1 µM E-64) and shaken at 4°C for 60 min. Lysed cells were centrifuged at 4°C at 100,000g for 30 min, and the pellets were homogenized in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) using a tight fitting Dounce homogenizer for 30 strokes. After centrifugation at 500g at 4°C for 20 min, the supernatant was centrifuged at 4°C at 100,000g for 60 min. The resulting pellet was resuspended in TS buffer and passed through a 27-gauge needle 30 times. Protein concentration was determined by a Bio-Rad protein assay kit. Crude membrane vesicles were dispensed in aliquots, frozen in liquid nitrogen, and stored at –80°C until use.
Immunoblotting. The membrane vesicle preparations were diluted in TS buffer. The indicated amount of protein was size fractionated on a 7.5% SDS-polyacrylamide gel and subsequently blotted on nitrocellulose membrane. Affinity-purified, polyclonal anti-human MRP2 (pAb hM2-p1) and anti-human MRP4 (pAb hM4-p4) antibodies (1:1000) were used to detect human MRP2 and MRP4, respectively (van Aubel et al., 2002; Smeets et al., 2004). Signals were visualized with chemiluminescence (Amersham Biosciences, Diegem, Belgium).
Vesicular Transport Assays. Uptake of [3H]MTX into membrane vesicles was performed as described previously (van Aubel et al., 1999). In brief, membrane vesicles were prewarmed for 1 min at 37°C and added to TS buffer, supplemented with an ATP-regeneration mixture (4 mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, and 100 mg/ml creatine kinase) in a final volume of 60 µl. The reaction mixture was incubated at 37°C for 15 min, and samples were taken from the mixture at indicated times, diluted in 900 µl of ice-cold TS buffer. Diluted samples were filtered through 0.45-µm-pore NC filters that were preincubated with TS buffer by a filtration device (Millipore, Bedford, MA) using a rapid filtration method. After adding 4 ml of scintillation fluid and subsequent liquid scintillation counting, uptake of [3H]MTX into membrane vesicles was studied by measuring radioactivity associated with the filters.
In control experiments, ATP was substituted with AMP. Net ATP-dependent transport was calculated by subtracting values measured in the presence of AMP from those measured in the presence of ATP. Measurements were corrected for the amount of ligand bound to the filters (usually <2% of total radioactivity). Each experiment was performed in triplicate. The sidedness of the membrane vesicles was not determined. ATP-dependent uptake can only occur in inside-out vesicles, and because inhibition by NSAIDs is expressed relatively as percentage of MTX uptake, the result is not affected by differences in expression levels and sidedness of the vesicles.
Transport Inhibition Assays. To evaluate the inhibitory effects of NSAIDs on MTX uptake mediated by MRP2 and MRP4, the previously mentioned transport assay was performed using 0.5 µM [3H]MTX, in the absence or presence of various concentrations of NSAIDs. Hydrophilic NSAIDs, viz. salicylate, diclofenac, tolmetin, ibuprofen, and naproxen, were dissolved in H2O. Hydrophobic NSAIDs, viz. sulindac, indomethacin, etodolac, ketoprofen, phenylbutazone, piroxicam, and celecoxib, were dissolved in dimethyl sulfoxide (DMSO) and diluted with incubation medium.
The final concentration of DMSO in the incubation medium was adjusted to less than 1% (Apiwattanakul et al., 1999). We tested the effect of 1% DMSO and observed a reduction of approximately 20% in transport. Because in all transport assays the same concentration of DMSO was used as a control, this reduction did not influence the results. In all experiments with hydrophobic NSAIDs, control samples contained the same concentration of DMSO.
Kinetic Analysis. All data were expressed as means ± S.E. IC50 values of NSAIDs were obtained from curve fitting of the resulting concentration-inhibition curves by nonlinear regression analysis using GraphPad Prism software version 4.03 (GraphPad Software Inc., San Diego, CA). Statistical differences were determined using a one-way analysis of variance with Dunnett's post test. Differences were considered to be significant at P < 0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; van Aubel et al., 2002) and 170-kDa (Lee et al., 2000; van Aubel et al., 2002) bands, respectively, whereas control MDCKII and HEK293 vesicles did not show any protein expression at the corresponding heights.
|
|
Concentration-Dependent Transport of MTX by MRP2 and MRP4. Membrane vesicles were incubated for 15 min at 37°C with 3H-labeled and unlabeled MTX to the final concentrations indicated (Fig. 3). ATP-dependent transport was calculated by subtracting the values obtained in the presence of AMP from those in the presence of ATP. MRP2- and MRP4-dependent uptakes were calculated by subtracting nonspecific uptakes in control MDCKII and HEK293 vesicles, respectively. MRP2 and MRP4 efficiently transported MTX, and the concentration of MTX at half-maximal uptake rates (Km) was relatively higher for MRP2 than for MRP4. The Km and Vmax values for MTX uptake in MRP2 and MRP4 vesicles were 480 ± 90 and 220 ± 70 µM and 80 ± 10 and 280 ± 30 pmol/mg/min, respectively. It should be noted that because of different expression systems, the enrichment of the transporters may be different, and therefore, it is only meaningful to compare Km values.
|
|
|
|
Figure 5 shows that etodolac was the only NSAID that gave a steep inhibition curve of MRP2-mediated MTX transport, with a slope factor significantly higher than one. Furthermore, the inhibitory pattern of diclofenac on MRP4-mediated transport and of indomethacin and ketoprofen on MRP2-mediated MTX transport could not be simply described according to a one-site competition model but was fitted significantly better using the two-site model. Phenylbutazone produced a bell-shaped curve against MRP2- but not MRP4-mediated transport, with significant stimulation up to 170 ± 16% at low and inhibition at higher concentrations. Celecoxib, the only selective cyclooxygenase II inhibitor tested, showed a mild but statistically significant stimulation of MRP4-mediated MTX transport at low concentrations. In contrast to what has been described by others (Zelcer et al., 2003), we could not find a stimulatory effect of indomethacin on MRP2-mediated MTX transport.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Although all NSAIDs tested are weak organic acids, they are chemically diverse and possess a wide range of pharmacokinetic characteristics, which makes it difficult to study the relationship between structure and inhibitory activity. In our study, sulindac had the highest and salicylate the lowest inhibitory potency for both MRP2 and MRP4. Etodolac was the only NSAID tested with an inhibitory curve with a slope factor significantly higher than unity, indicating positive co-operativity in inhibition. Most NSAIDs had a higher inhibitory potency against MRP4- than MRP2-mediated transport. The effect of diclofenac on MRP4 and of indomethacin and ketoprofen on MRP2 exhibited a two-site competition model. Furthermore, phenylbutazone and celecoxib showed a dual effect. At low concentrations, phenylbutazone had a strong stimulatory effect on MTX transport via MRP2 but not MRP4, whereas celecoxib stimulated MRP4 transport modestly. At higher concentrations, phenylbutazone and celecoxib inhibited both transporters. This is compatible with the suggestion that both MRP2 (Zelcer et al., 2003) and MRP4 (van Aubel et al., 2005) have more than one binding site. This phenomenon was previously explained by the existence of two independent binding sites, one site that transports substrates and another site that can allosterically modulate the substrate transport site (Zelcer et al., 2003). Compounds that can stimulate as well as inhibit transport probably bind at low concentrations preferentially to the modulatory site, whereas at high concentrations, they can also compete for the substrate transport site. This type of allosteric interaction seems a common characteristic of the MRPs.
Several NSAIDs belonging to the selective cyclooxygenase II inhibitors were reported not to affect the clinical pharmacokinetics of MTX (Schwartz et al., 2001; Hartmann et al., 2004), including celecoxib (Karim et al., 1999). This may be due to the low immunosuppressive MTX dosages used in these studies. Our results show that celecoxib can be a potent inhibitor of MRP2- and MRP4-mediated renal MTX efflux.
The MTX concentration of 0.5 µM we used in the inhibition experiments is relatively low as compared with plasma concentrations after therapeutic dosages, which are highly variable and may range from 0.1 up to 20 to 50 µM. Because of tubular accumulation of MTX via active uptake, it is likely that intracellular concentrations will exceed the plasma concentration. Apparently, MRP4 transports MTX with higher affinity than MRP2. Previous studies reported that Km values of MTX were higher for MRP2 (2.5–3 mM) (Bakos et al., 2000) than for MRP4 (0.22–1.3 mM) (Chen et al., 2002; van Aubel et al., 2002), which is in line with our results. In addition, the protein expression of MRP4 is 5-fold higher than MRP2 in human kidney cortex (Smeets et al., 2004). Furthermore, by comparing the IC50 values of different NSAIDs, we found that NSAIDs generally exhibited a higher inhibitory potency against MRP4. Given this information, we would expect that MRP4 plays a more important role than MRP2 in the inhibition of renal MTX efflux by NSAIDs. On the other hand, a recent study in Mrp2–/– mice showed 1.8-fold higher plasma concentrations of MTX as compared with wild-type mice. Although Mrp4 expression was increased 2-fold in the knockouts, apparently it was not able to compensate for the loss of Mrp2 in these mice (Vlaming et al., 2006). Furthermore, it was reported that in a patient with MRP2 protein dysfunction caused by a genetic variation in the MRP2/ABCC2 gene, MTX excretion was impaired, leading to severe overdose manifestations as nephrotoxicity, amounting to renal failure (Hulot et al., 2005). The apparent contradiction between the expected higher effects of MRP4 participating in MTX elimination at the molecular level needs further investigation. It is hard to define the relative influence of a certain NSAID on the urinary excretion of MTX, making it very difficult to recommend a specific NSAID with the lowest interaction potential in patients. In addition to the inhibitory potency of the NSAIDs, a number of other factors should be taken into consideration: the variation in NSAID dosing, which, in case of salicylate, may reach gram quantities per day producing serum concentration ranging from several hundred micromolars to several millimolars (Cerletti et al., 2003), the concentration of unchanged NSAIDs reached in proximal tubular cells by carrier-mediated uptake, and the possible effects of NSAID metabolites on MTX efflux. Because of extensive plasma protein binding ranging from 90 to 99%, the unbound concentrations of NSAIDs in plasma are low. The estimated unbound therapeutic concentration of the most potent inhibitors, sulindac and indomethacin, are approximately 1 and 8 µM, respectively, which is in the range of their IC50 values for MRP4 (Davies and Skjodt, 2000; Takeda et al., 2002; Chen et al., 2006). For the other NSAIDs tested, unbound plasma concentrations are considerably lower than their IC50 values, but it should be noticed that some of these compounds are also actively taken up in the proximal tubular cells by organic anion transporters, resulting in much higher concentrations to which MRP2 and MRP4 will be exposed (Apiwattanakul et al., 1999).
In summary, our study shows that MRP2- and MRP4-mediated efflux of MTX can be inhibited by various NSAIDs at therapeutically relevant concentrations. Because MRP2 and MRP4 are important efflux transporters for MTX in the kidney, they are potential new sites of MTX-NSAIDs interaction. The relative contribution of this mechanism to the overall inhibition of renal MTX excretion by NSAIDs and the individual roles of MRP2 and MRP4 herein need to be established in future in vivo studies.
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drug; OAT/Oat, organic anion transporter; MRP/Mrp, multidrug resistance protein; MDCKII, Madin-Darby canine kidney; HEK, human embryonic kidney; DMSO, dimethyl sulfoxide; E-64, N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide.
Address correspondence to: Dr. Frans G. M. Russel, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Department of Pharmacology and Toxicology 149, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: F.Russel{at}ncmls.ru.nl
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, and Endou H (1999) Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol 55: 847–854.
Bakos E, Evers R, Sinko E, Varadi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57: 760–768.
Cassano WF (1989) Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 11: 481–482.[Medline]
Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, and de Gaetano G (2003) Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 42: 1059–1070.[CrossRef][Medline]
Chen YL, Jong YJ, and Wu SM (2006) Capillary electrophoresis combining field-amplified sample stacking and electroosmotic flow suppressant for analysis of sulindac and its two metabolites in plasma. J Chromatogr A 1119: 176–182.
Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62: 3144–3150.
Davies NM and Skjodt NM (2000) Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin Pharmacokinet 38: 377–392.[CrossRef][Medline]
Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, and Endou H (2004) Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 94: 297–304.[CrossRef][Medline]
Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Investig 101: 1310–1319.[Medline]
Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, Chales GH, Juvin RR, Lafforgue P, Le Parc JM, Tavernier CG, and Meyer OC (2004) Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann Pharmacother 38: 1582–1587.
Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, et al. (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15: 277–285.[Medline]
Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, and Geis GS (1999) Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 26: 2539–2543.[Medline]
Kremer JM and Hamilton RA (1995) The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 22: 2072–2077.[Medline]
Lee K, Klein-Szanto AJ, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92: 1934–1940.
Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, and Sugiyama Y (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57: 3506–3510.
Nozaki Y, Kusuhara H, Endou H, and Sugiyama Y (2004) Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 309: 226–234.
Reid G, Wielinga P, Zelcer N, van dH I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100: 9244–9249.
Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, Storkel S, Thon WF, and Keppler D (1999) Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10: 1159–1169.
Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W, and Keppler D (1997) Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8: 1213–1221.[Abstract]
Schwartz JI, Agrawal NG, Wong PH, Bachmann KA, Porras AG, Miller JL, Ebel DL, Sack MR, Holmes GB, Redfern JS, et al. (2001) Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol 41: 1120–1130.[Abstract]
Sekine T, Watanabe N, Hosoyamada M, Kanai Y, and Endou H (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272: 18526–18529.
Singh RR, Malaviya AN, Pandey JN, and Guleria JS (1986) Fatal interaction between methotrexate and naproxen. Lancet 1: 1390.[Medline]
Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, and Russel FG (2004) Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol 15: 2828–2835.
Stewart CF, Fleming RA, Germain BF, Seleznick MJ, and Evans WE (1991) Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 34: 1514–1520.[Medline]
Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, and Endou H (2002) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302: 666–671.
Thyss A, Milano G, Kubar J, Namer M, and Schneider M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256–258.[Medline]
Tong CT, Howard SA, Shah HR, Van Quill KR, Lin ET, Grossniklaus HE, and O'Brien JM (2005) Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol 89: 1217–1220.
van Aubel RA, Koenderink JB, Peters JG, van Os CH, and Russel FG (1999) Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 56: 714–719.
van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. JAm Soc Nephrol 13: 595–603.
van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol 288: F327–F333.
Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, et al. (2006) Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318: 319–327.
Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, and Borst P (2003) Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 278: 23538–23544.
This article has been cited by other articles:
|
|
 |
|
  R. M. Pelis, M. Shahidullah, S. Ghosh, M. Coca-Prados, S. H. Wright, and N. A. Delamere Localization of Multidrug Resistance-Associated Protein 2 in the Nonpigmented Ciliary Epithelium of the Eye J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 479 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lagas, C. M. M. van der Kruijssen, K. van de Wetering, J. H. Beijnen, and A. H. Schinkel Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone Drug Metab. Dispos., January 1, 2009; 37(1): 129 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, E. Krieger, F. G. M. Russel, and J. B. Koenderink Functional Role of Arginine 375 in Transmembrane Helix 6 of Multidrug Resistance Protein 4 (MRP4/ABCC4) Mol. Pharmacol., October 1, 2008; 74(4): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Heredi-Szabo, E. Kis, E. Molnar, A. Gyorfi, and P. Krajcsi Characterization of 5(6)-Carboxy-2,'7'-Dichlorofluorescein Transport by MRP2 and Utilization of this Substrate as a Fluorescent Surrogate for LTC4 J Biomol Screen, April 1, 2008; 13(4): 295 - 301. [Abstract] [PDF]
|
|
|
|
|
|
Z. P. Lin, Y.-L. Zhu, D. R. Johnson, K. P. Rice, T. Nottoli, B. C. Hains, J. McGrath, S. G. Waxman, and A. C. Sartorelli Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response Mol. Pharmacol., January 1, 2008; 73(1): 243 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1162 - 1170. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
) or MRP2-expressing (
) MDCKII cells and control (
) or MRP4-expressing (
) HEK293 cells. Data present mean and S.E. of at least three different experiments, each performed in triplicate.
